Heron Therapeutics
Heron Therapeutics makes long-acting supportive-care injectables: the antiemetics Sustol (extended-release granisetron) and Cinvanti (aprepitant emulsion), plus the post-surgical analgesic Zynrelef.
Overview
Heron's polymer-based extended-release technology underlies Sustol (granisetron, approved 2016 for chemotherapy-induced nausea and vomiting) and Cinvanti (intravenous aprepitant, 2017); Aponvie (aprepitant) and Zynrelef serve the surgical market.
Scorecard
All companies- approved products +12
- modalities +2
- regions +2
- registry trials +26
Aprepitant (Emend) was the first of a new class of anti-sickness drugs. Taken with a 5-HT3 blocker and dexamethasone, it prevents the delayed nausea and vomiting that follow strongly emetogenic chemotherapy such as cisplatin.
Granisetron is an anti-sickness medicine for chemotherapy given as a tablet, an injection, a week-long skin patch (Sancuso) or a slow-release injection that lasts several days (Sustol).
Pages like this
not linked directly; found by shared links- ProductOndansetron
- ProductPalonosetron
- TechnologyAntiemetics for chemotherapy-induced nausea and vomiting